Journal of the American Society of Hypertension
Volume 2, Issue 3 , Pages 131-139, May 2008

Role of statin therapy in stroke prevention

  • Jason M. Morda, MD
    • ,
  • Michael J. Ranella, BS
    • ,
  • Robert S. Rosenson, MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Robert S. Rosenson, MD, Division of Cardiovascular Medicine, University of Michigan, Domino's Farms, 24 Frank Lloyd Wright Drive, Lobby A 3rd Floor, Ann Arbor, Michigan 48106. Tel: 734-998-4992; fax: 734-998-9587.

Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA

Received 1 August 2007; accepted 11 December 2007.

Abstract 

Serum cholesterol levels have been associated with atherosclerosis and the lowering of serum cholesterol with hydroxy-methyl coenzyme A reductase inhibitors, or statins, has been shown to decrease cardiovascular events. Though early epidemiologic data found conflicting results regarding serum cholesterol levels and stroke, randomized clinical trials of statins for coronary heart disease prevention showed a clear reduction in the incidence of stroke. This review summarizes the clinical trial data surrounding lipid lowering for stroke prevention while also exploring potential mechanisms for such an effect. Particular attention is given to trials for primary and secondary prevention of stroke relevant to the hypertensive individual, and the impact of hemorrhagic vs. ischemic stroke in the outcomes of these trials.

Keywords: High-density lipoprotein cholesterol, hypertension, low-density lipoprotein cholesterol, hydroxy-methyl coenzyme A reductase inhibitors

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Rosenson has received funds from Astra Zeneca (speaker's bureau, honoraria payment).

 Conflict of interest: none.

PII: S1933-1711(07)00253-7

doi:10.1016/j.jash.2007.12.003

Journal of the American Society of Hypertension
Volume 2, Issue 3 , Pages 131-139, May 2008

Article Tools

* Image Usage & Resolution